<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:chebi fb="0" ids="20551">5-aminosalicylates</z:chebi> (<z:chebi fb="0" ids="6775">5-ASA</z:chebi>) are widely used to treat patients with <z:hpo ids='HP_0100279'>ulcerative colitis</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>Experimental data suggest that these agents can potentially be used in a chemopreventive fashion to inhibit the development of <z:hpo ids='HP_0002583'>colitis</z:hpo>-associated <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>); however, observational studies investigating a possible risk reduction of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> by <z:chebi fb="0" ids="6775">5-ASA</z:chebi> therapy have revealed conflicting results </plain></SENT>
<SENT sid="2" pm="."><plain>Currently, it appears that <z:chebi fb="0" ids="6775">5-ASA</z:chebi> have no or only a very limited effect as a deterrence against <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>Thus, a general recommendation for long-term use of <z:chebi fb="0" ids="6775">5-ASA</z:chebi> solely for chemopreventive measures is not warranted </plain></SENT>
</text></document>